Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$5.65B
sum of reported positions
Reported positions
543
Changes vs prior quarter
567
60 new · 52 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 344 measured positions in 8 quarters, the typical new or larger position finished −1.0 pts against the S&P 500 and 48% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 592K | $72.4M | 1.3% | |
| 109K | $62.8M | 1.1% | |
| 652K | $62.7M | 1.1% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $4.72B | $5.65B |
| Positions | 535 | 543 |
| Biggest line | — | Mercury Systems 1% |
| 848K |
| $62.4M |
| 1.1% |
| 565K | $55M | 1.0% |
| 690K | $48M | 0.8% |
| 659K | $47.7M | 0.8% |
| 1.58M | $47.2M | 0.8% |
| 611K | $46.4M | 0.8% |
| 1.63M | $45.7M | 0.8% |
| 149K | $44.2M | 0.8% |
| 545K | $42.7M | 0.8% |
| 112K | $42.4M | 0.7% |
| 426K | $41.5M | 0.7% |
| 172K | $40.1M | 0.7% |
| 357K | $40.1M | 0.7% |
| 234K | $37.6M | 0.7% |
| 540K | $37.6M | 0.7% |
| 227K | $37.3M | 0.7% |
| 601K | $36.8M | 0.7% |
| 230K | $35.7M | 0.6% |
| 345K | $34.4M | 0.6% |
| 660K | $34.4M | 0.6% |
| 670K | $34.3M | 0.6% |
| 479K | $33.4M | 0.6% |
Renasant Corp. (RNST)
26K shares
Bankwell Financial Group (BWFG)
25K → 19K shares (−24%)
Alnylam Pharmaceuticals (ALNY)
3,503 → 3,607 shares (+3%)
First Busey Corp (BUSE)
38K → 37K shares (−4%)
Trimble Inc. (TRMB)
15K → 20K shares (+32%)
Cencora (COR)
3,776 → 3,584 shares (−5%)
First Carolina Financial Services (FCBM)
75K shares
Natera (NTRA)
3,503 → 3,607 shares (+3%)
Cullinan Therapeutics (CGEM)
51K → 53K shares (+3%)
Cra International (CRAI)
6,703 → 6,588 shares (−2%)
Perella Weinberg Partners (PWP)
60K → 59K shares (−2%)
Amneal Pharmaceuticals (AMRX)
51K → 48K shares (−5%)
Blue Ridge Bankshares (BRBS)
229K → 220K shares (−4%)
Viatris (VTRS)
46K → 44K shares (−5%)
Zoetis (ZTS)
8,496 → 8,064 shares (−5%)
Sionna Therapeutics (SION)
12K → 13K shares (+3%)
Smartfinancial (SMBK)
24K → 11K shares (−52%)
Intellia Therapeutics (NTLA)
29K → 30K shares (+3%)
Atrium Therapeutics (RNA)
34K → 35K shares (+3%)
Engene Therapeutics (ENGN)
269K shares
Valero Energy (VLO)
1,485 → 1,399 shares (−6%)
Goldman Sachs (GS)
314 → 296 shares (−6%)
JPMorgan Chase (JPM)
932 → 878 shares (−6%)
MACOM Technology Solutions (MTSI)
105K → 748 shares (−99%)
RTX (RTX)
1,524 → 1,436 shares (−6%)
